SCM LifeScience Co

SCM LifeScience Co EBITDA Margin

The EBITDA Margin of SCM LifeScience Co (298060.KQ) as of Nov 19, 2026 is -19.00 %. In the previous year, EBITDA Margin was -1,475.61 % — a change of -98.71% (higher).

EBITDA Margin

-19.00 %

YoY

-98.71%

Last updated:

EBITDA Margin of SCM LifeScience Co is 2025 -19.00 % . EBITDA Margin of SCM LifeScience Co was 2024 -1,475.61 % . It decreases by -98.71% higher compared to the previous year.

The SCM LifeScience Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2017
-17,197.03 KRW
Jan 1, 2018
-28,677.35 KRW
Jan 1, 2020
-4,642.91 KRW
Jan 1, 2021
-2,507.14 KRW
Jan 1, 2022
-2,913.87 KRW
Jan 1, 2023
-3,291.60 KRW
Jan 1, 2024
-1,475.61 KRW
Jan 1, 2025
-19.00 KRW
The SCM LifeScience Co EBITDA Margin history
YEAREBITDA MarginYoY
-19.00 %-98.71%
-1,475.61 %-55.17%
-3,291.60 %+12.96%
-2,913.87 %+16.22%
-2,507.14 %-46.00%
-4,642.91 %-83.81%
-28,677.35 %+66.76%
-17,197.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

EBITDA Margin of SCM LifeScience Co is -19.00 % in 2025.

EBITDA Margin of SCM LifeScience Co changed from -1,475.61 % to -19.00 %, representing a -98.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's SCM LifeScience Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co